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Preface 
 Apoptotic cell death is widely considered a positive process that serves 
to both prevent and treat cancer. While undoubtedly playing a beneficial role, 
paradoxically, apoptosis can also cause unwanted effects that may even 
promote cancer. In this opinion article we highlight some of the ways through 
which apoptosis can exert oncogenic function. We argue that fully 
understanding this dark-side will be required in order to optimally engage 
apoptosis, thereby maximising tumour cell kill while minimizing unwanted 
effects. 
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Introduction 
Apoptosis is a major type of regulated cell death in our bodies. This 
evolutionary conserved process plays crucial roles that range from tissue 
sculpting during embryonic development through to execution of immune 
effector functions 1. Moreover, too much or too little apoptosis has been 
implicated in diverse diseases including neuro-degeneration and auto-
immunity 2, 3. Abundant evidence supports a role for inhibition of apoptosis in 
the promotion of cancer and blunting of therapeutic responses 4-6. 
Accordingly, significant excitement surrounds engaging apoptosis in a tumour-
specific manner in order to treat cancer; to this end, highly promising 
apoptosis-inducing therapies called BH3-mimetics are in advanced clinical 
trials for the treatment of chronic lymphocytic leukemia (CLL) 7. Therefore, 
apoptosis is widely considered a positive process that serves to both inhibit 
and treat cancer. In this opinion article we present a more nuanced view of 
apoptosis, namely that it can also have cancer-promoting functions. We begin 
our discussion by providing a general overview of apoptotic signaling before 
briefly reviewing its role in restraining cancer. From this basis, we highlight the 
varied means by which apoptotic signaling can exert oncogenic effects; these 
include extrinsic effects of the dying cell, intrinsic effects due to surviving 
apoptotic stress or due to non-apoptotic functions of proteins typically 
considered apoptotic. We propose that improved understanding of these 
effects and their importance in cancer should optimise our ability to fully 
exploit apoptosis as a therapeutic mechanism. 
 
Apoptotic signaling pathways 
Caspase protease activity is essential for the morphological and 
biochemical hallmarks of apoptosis 8. In broad terms, caspases can be 
activated through one of two pathways - the extrinsic (also called death-
receptor) pathway and the intrinsic (also called mitochondrial) pathway 
(Figure 1). As the name implies, the extrinsic pathway requires external 
stimulation, this occurs via a death receptor-family member, such as TRAIL-
R1 (DR4), TRAIL-R2 (DR5), CD95 (FAS) or TNF-R1, located at the plasma 
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membrane. Following ligand binding, death receptors activate caspases 
leading to widespread substrate protein cleavage and rapid cell death 8.  
 
 The intrinsic apoptotic pathway is engaged by a wide array of stimuli 
that are sensed intra-cellularly including cytokine deprivation, DNA damage 
and endoplasmic reticulum (ER) stress (Figure 1). As we will discuss, the 
intrinsic apoptotic pathway is often deregulated in cancer. These diverse 
apoptotic stresses converge to trigger one critical event - mitochondrial outer 
membrane permeabilisation or MOMP 9. The extrinsic and intrinsic pathways 
also crosstalk through caspase-8 cleavage of the BH3-only protein BID - this 
generates the active, truncated form of BID (tBID) that triggers MOMP 10, 11. 
Following mitochondrial permeabilisation cytochrome c is released from the 
mitochondrial intermembrane space and induces caspase activation via a 
cytoplasmic complex termed the apoptosome 9. Importantly, because MOMP 
often kills irrespective of caspase activity, it is considered a cellular death 
sentence 12. Nevertheless, there are notable exceptions; for example some 
types of neurons can circumvent the lethal effect of MOMP by inhibiting 
caspase activity through various means including low expression of APAF-1 
or degradation of cytochrome c 13, 14. Moreover, proliferating cells under 
caspase-inhibited conditions can also survive MOMP dependent upon 
glycolytic metabolism and autophagy 15. 
 
Because of this pivotal role in dictating life and death, MOMP is highly 
regulated through interactions between Bcl-2 family members 16. There are 
three subfamilies of Bcl-2 proteins: anti-apoptotic Bcl-2 proteins (such as 
BCL-2 or BCL-xL), pro-apoptotic BH3-only proteins (including PUMA, BID and 
BIM) and pro-apoptotic effector proteins (BAX, BAK and BOK). BH3-only 
proteins relay diverse apoptotic signals to activate BAX and BAK at the 
mitochondrial outer membrane whereupon BAX and BAK trigger MOMP 16. 
Anti-apoptotic Bcl-2 proteins inhibit MOMP and cell death either by directly 
binding BH3-only proteins or by binding activated BAX and BAK 17. This is 
therapeutically important since competitive disruption of these interactions -
thereby sensitizing to apoptosis- forms the mechanistic basis of BH3-mimetic 
action 18. 
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Apoptosis in the prevention and treatment of cancer 
 Apoptosis has long-been considered a process that must be evaded in 
order to allow cancer to develop 4. This view is supported by a wealth of data, 
including: 1) demonstration that inhibition of cell death, in combination with 
mitogenic oncogenes, can promote cancer in experimental models 19-21 2) 
discovery that many oncogenic pathways inhibit apoptosis, whereas tumour 
suppressors, such as p53, can engage apoptosis 22 3) positive correlation 
between tumour cell apoptotic sensitivity and therapeutic efficacy in patient 
derived cancer cells  23, 24 4) frequently observed up-regulation of anti-
apoptotic proteins in cancer 25. Nevertheless, while inhibition of apoptosis may 
promote cancer, cancer cells are often not inherently apoptosis-resistant. 
Indeed, as we will highlight, some human tumour types are actually more 
sensitive to apoptosis than normal tissue 26, 27. Counter-intuitively, higher 
levels of apoptosis in cancer patients have also been shown to correlate with 
poorer prognosis in some cancer types 28-33. Finally, and again paradoxically, 
high-levels of anti-apoptotic proteins correlate with better prognosis in certain 
cancers. For example, as shown in Table 1, a high level of anti-apoptotic Bcl-
2 protein expression associates with favourable outcome in some human 
cancers. Notably, increased anti-apoptotic Bcl-2 protein expression does not 
necessarily translate to decreased apoptotic sensitivity, indeed the opposite 
can hold true. For example, some cancers, such as CLL, express high levels 
of anti-apoptotic Bcl-2 proteins to buffer intrinsic pro-apoptotic Bcl-2 activity 34. 
Cancer cells in this state are referred to as “primed for death” and are highly 
sensitive to apoptosis-inducing therapies 26. Whereas increased-expression of 
anti-apoptotic BCL-2 proteins can associate with good prognosis, high-
expression of pro-apoptotic BAX can correlate with a poor outcome (Table 1). 
As we now discuss, these findings and others challenge the view that 
apoptotic signaling serves solely to inhibit cancer, arguing instead that 
apoptosis also has a dark-side that can actually promote cancer. 
 
Calling from beyond the grave: cell extrinsic effects of tumour cell 
apoptosis 
 6
 While apoptotic cell death is a cell-autonomous event, its effects are 
not; dying cells impact on their surrounding environment in various, yet not 
fully understood, ways. These can include stimulating the proliferation of 
neighbouring cells, impacting on intra-tumoural cell competition as well as 
exerting paracrine effects on the tumour microenvironment. By serving to 
promote cancer progression, they also represent potential nodes for 
therapeutic intervention. 
(Unwanted) Life after death - apoptosis induced proliferation 
 Apoptotic cells can actively promote the proliferation of surrounding 
cells. As a physiological event, this may allow apoptotic cells within a tissue to 
signal their replacement either during normal turnover or serve as a healing 
response following extensive tissue damage. This process has been best 
studied in the fruit-fly Drosophila melanogaster where cells undergoing 
apoptosis in the imaginal disk were shown to activate mitogen-signaling, 
promoting the proliferation of neighboring cells 35-37.  
 
 Directly relevant to cancer, apoptosis-induced proliferation also occurs 
in mammalian settings. Apoptotic cells can stimulate the proliferation of stem 
cells in a caspase-dependent manner 38. Moreover, genetic deletion of 
caspases-3 and -7 inhibits regeneration in two model systems - skin wound 
healing and liver regeneration following partial hepatectomy 38. How can 
apoptotic cells stimulation proliferation? Various studies have implicated 
prostaglandin E2 (PGE2) as a key mediator of apoptosis-induced proliferation 
in mammalian systems. During apoptosis, caspases cleave and activate 
iPLA2 (calcium-independent phospholipase A2) increasing the production of 
arachidonic acid (AA), which is converted via cyclooxygenases 1 and 2 
(COX1 and 2) to PGE2 39. This may provide a mechanistic explanation to 
intriguing observations made in the 1950's that mixing of viable tumour cells 
together with cells destined to die actually accelerated tumour growth, a 
finding subsequently observed by others 40, 41 (Figure 2). Indeed recent data 
argue that signalling by apoptotic tumour cells, plays an important role in 
tumour re-growth following radiotherapy 42. Tumour repopulation in a mouse 
xenograft model of breast cancer is promoted in a caspase-3 and iPLA2 
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dependent manner, likely through the production of PGE2 42. In bladder 
cancer, production of PGE2 by apoptotic tumour cells promotes 
chemoresistance by stimulating cancer stem cell proliferation 43. The 
therapeutic relevance of targeting apoptosis-induced proliferation is supported 
by the finding that neutralisation of PGE2 signalling reduced the emergence of 
chemoresistance in a model of human bladder cancer 43. Importantly, PGE2 
has pleiotropic functions, for example, not only does it promote proliferation, 
but it can also serve to skew immune responses towards a tumour-promoting, 
anti-inflammatory phenotype 44. In doing so, generation of PGE2 by apoptotic 
tumour cells could have dual tumour promoting functions - simultaneously 
driving proliferation and inhibiting anti-tumour immunity.  
Apoptosis, cell competition and cancer  
 Many influences, including the availability of nutrients and growth 
factors, all combine to impact on a cell's ability to grow. Proliferating cells 
constantly compete with one another; "winner" cells outcompete "loser" cells 
either by, for example, taking-up nutrients more effectively - or through 
elimination of the competition. Apoptosis can contribute to the latter effect, 
generating a vacant niche into which cancerous cells can expand. The key 
tumour suppressor protein, p53 prevents cancer through multiple mechanisms 
45. In a transplantable mouse model of lymphoma, deletion of p53 from 
hematopoietic progenitors per se does not confer a competitive advantage 
over wild-type cells unless the system is stressed (in this case by irradiation) 
46, 47. p53-deficient cells survive irradiation whereas wild-type cells are 
eliminated by p53 activity (either through apoptosis, cell cycle arrest or 
senescence). This provides a vacant niche into which p53-deficient can 
proliferate, facilitating the accumulation of genetic lesions that lead to cancer.  
 
Similarly, a direct role for apoptosis in promoting cancer by killing off 
the healthy competition has been shown in PUMA-deficient mice.  The BH3-
only protein PUMA is essential for p53-mediated apoptosis in thymocytes and 
its loss enhances myc-induced lymphomagenesis 48-51. Counter-intuitively, 
loss of PUMA prevents rather than promotes thymic lymphoma following 
irradiation 52, 53. Similarly, in a carcinogen-induced liver cancer model, deletion 
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of PUMA or overexpression of anti-apoptotic BCL-2 protein also delays 
tumour development 54, 55. Finally, deletion of another pro-apoptotic BH3-only 
protein - BID - inhibits rather than promotes hepatocarcinogenesis following 
different chronic liver injury insults 56, 57. Why would inhibition of apoptosis 
prevent rather than promote cancer? The answer likely relates to our earlier 
discussion of p53 and cell competition. As the authors propose, PUMA 
mediated apoptosis of healthy cells could remove the competitive pressure 
that normally acts to restrain proliferation of aberrant cells, in doing so this 
leads to cancer. In support, glucocorticoid treatment eliminates cells in a 
PUMA-independent manner and leads to thymic lymphoma in PUMA-deficient 
mice 52. Relating to our earlier discussion, particularly in liver cancer, 
apoptosis may also promote cancer by actively engaging compensatory 
proliferation of neighbouring cells 54.   
 
 At least in mice, these studies strongly support a cancer-promoting role 
for apoptosis through an ability to generate a vacant niche. However, to what 
extent might the role of apoptosis in competition affect human malignancies? 
One possibility is in the development of myelodysplatic syndrome (MDS) that 
can progress to MDS related acute myeloid leukaemia (MDR-AML) 58. MDS is 
a blood disease that leads to sudden blood cell cytopenia. In many cases its 
etiology is unknown but its increasing incidence with age strongly suggests 
that cumulative damage plays a major role. MDS is also a relatively common, 
secondary consequence of DNA-damaging cancer therapy. MDS leading to 
MDR-AML are malignancies that arise as a clonal disease of hematopoietic 
stem cells (HSCs). Through successive rounds of DNA-damage, proliferation 
and apoptosis, clones are selected that ultimately give rise to AML 58. The role 
of apoptosis in this disease may be multi-faceted, but one possibility is that, 
similar to the PUMA models described above, a proportion of highly 
apoptosis-sensitive HSCs die leaving a vacant niche that mutated HSCs fill. In 
a ramped-up process of Darwinian selection, rounds of these events, may 
lead to the development of aggressive and apoptosis resistant AML. Indeed, 
supporting this idea, inhibiting apoptosis, either through ectopic BCL-2 
expression or loss of PUMA expression delays leukemia progression in 
mouse models of MDS 59, 60. As the authors suggest, if these findings hold 
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true in humans, inhibition of apoptosis may actually delay MDS progression. 
Through similar means, engagement of apoptosis by cancer therapies may 
also inadvertently promote more aggressive disease.  In this scenario, killing 
of sensitive cancer cells (losers) may remove competitive pressure allowing 
aggressive clones to dominate and win (Figure 2).  
Pro-oncogenic effects of apoptotic cells upon the tumour 
microenvironment  
 An estimated one million cells in our bodies undergo apoptosis every 
second 1. Nevertheless, analysis at any given timepoint fails to reveal this 
wholesale carnage, largely because apoptotic cells are efficiently engulfed 
and destroyed by phagocytic cells. Caspase-dependent events actively 
orchestrate recruitment of phagocytes towards the apoptotic cell, by releasing 
"find-me" signals and promote the engulfment of the dying cell by exposing 
"eat-me" signals 61. Several "find-me" signals released by apoptotic cells have 
been identified including the lipid lysophosphatidylcholine (LPC), nucleotides 
such as ATP, the proteins fractalkine (also called CX3CL1 or FKN) and 
lactoferrin (LTF) (Figure 2). These signals may exert oncogenic function 
through pleiotropic effects that include but are not limited, to their role as "find-
me" signals. For example, fractalkine can stimulate angiogenesis in vitro, 
hypoxia-induced proliferation of prostate cancer cells and enhance oncogenic 
ERBB2 receptor signaling 62,63.  Besides being a powerful chemokine 
released by apoptotic cells 64, ATP can also have a major influence on 
cancer. While numerous studies support an anti-tumorigenic effect of ATP, 
there is increasing realisation that adenosine (a degradation product of 
extracellular ATP), can be oncogenic, supporting tumour growth, 
angiogenesis and immune-escape 65. Various data also support the idea 
apoptosis can promote tumourigenesis through the recruitment and activation 
of phagocytic macrophages at the tumour site. For example, different studies 
have found high levels of apoptosis or macrophage infiltration associate with 
poor prognosis for cancer patients 28-31, 66. 
 
 Is there a relationship between tumour-associated macrophages 
(TAM), apoptosis and cancer progression? Similar to wound-healing 
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macrophages, TAM promote tissue-remodeling and angiogenesis while 
exerting anti-inflammatory effects. In doing so, TAM promote cancer 
progression 67. Because apoptotic cells are in close proximity with TAM in the 
tumoural milieu, a possible functional interconnection is possible. Direct 
support for a causal effect has come from recent research demonstrating that 
inhibition of mitochondrial apoptosis in a mouse model of B-cell lymphoma 
impairs angiogenesis and tumour growth 68. This implicates non-autonomous 
effects of apoptosis in the promotion of tumour cell growth  (Figure 2). The 
pro-oncogenic effect of apoptotic cells also extended to different other cancer 
types since altering apoptotic tumour cell level in transplantable mouse 
models of λ-MYC B lymphoma and melanoma also affected tumourigenesis; 
removal of apoptotic cells from the transplant inoculum delayed 
tumourigenesis whereas addition of apoptotic cells had the opposite effect, 
enhancing tumourigenesis. Importantly, TAM infiltration within tumours directly 
correlated with levels of tumour cell apoptosis - in apoptosis proficient 
tumours TAM infiltration was much higher than in apoptosis deficient settings. 
These results, together with transcriptomic and in vitro co-culture experiments 
led the authors to propose a model whereby tumour cell apoptosis reprogram 
TAM towards a wound-healing type response that fuels tumourigenesis 68. 
This study provides strong experimental evidence that apoptotic cells can 
promote tumourigenesis. Clearly many questions remain, not least in 
understanding how apoptotic tumour cells promote TAM activation.  
 
 Besides promoting tumour growth, apoptotic cells may also facilitate 
metastatic tumour progression 69. It is well known that pregnancy reduces the 
overall risk of developing breast cancer; however when breast cancer is 
diagnosed in postpartum women it is often more aggressive and has a poorer 
prognosis compared to disease diagnosed in nulliparous women 70. 
Potentially contributing to this, postpartum involution is characterised by 
massive cell death leading to extensive efferocytosis (clearance of dead 
cells).  Implicating the clearance of apoptotic cells in cancer progression, a 
recent study in an MMTV-PyMT mouse model of breast cancer found that a 
high level of efferocytosis in parous animals promoted TAM infiltration, 
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stimulation of a wound-healing cytokine response and increased metastasis 
69.  
 
The enemy within: oncogenic effects of apoptosis signaling at the 
cell-intrinsic level   
 Here we address oncogenic effects of engaging apoptosis at the single 
cell level. The only way in which apoptosis can exert oncogenic potential in a 
cell intrinsic manner is if the cell in question can survive apoptosis signalling. 
Following our discussion of this, we present an overview of emerging 
evidence, which argues that proteins, generally considered apoptotic, can 
exert oncogenic functions through non-apoptotic mechanisms. 
 
Failed apoptosis and cancer  
 Recent data show that cells which initiate apoptosis but do not die –we 
term this failed-apoptosis– sustain potentially oncogenic damage such as 
genomic instability and gene amplification (Figure 3) 71-73. The failure to 
commit suicide is puzzling given what we know about apoptosis. First, 
activation of caspases can unleash a variety of feed-forward mechanisms to 
fully engage apoptosis 10, 11. Secondly, live-cell imaging studies have shown 
that during apoptosis, MOMP itself is an explosive event that occurs in all 
mitochondria over a ten-minute window 74, 75. Finally, the level of caspase 
activity that is required to kill a cell does not appear to be very high 76. These 
points notwithstanding, various studies have found that cells can engage 
caspase activity and survive, sustaining damage in the process 71-73, 70 
 
 Intense interest has surrounded the potential of TRAIL ligands as anti-
cancer therapies because many tumour-types are selectively sensitive to 
TRAIL-mediated apoptosis 77. One of the first studies that demonstrated 
engagement of caspases activity in the absence of cell death focused on 
TRAIL-induced apoptosis 78. The authors found that under conditions where 
MOMP was inhibited and XIAP function was compromised (thereby facilitating 
executioner caspase activity) TRAIL treated cells could engage limited 
executioner caspase activation yet survive – an example of failed-apoptosis. 
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Supporting an oncogenic role for failed apoptosis following TRAIL-treatment, 
another study found that sub-lethal doses of TRAIL (and FAS ligand) led to 
caspase-dependent mutations and genomic instability in surviving cells 72. 
Why might limited caspase activity prove oncogenic? The answer relates to 
specific caspase substrates; one caspase-dependent hallmark of apoptosis is 
extensive DNA fragmentation that is mediated by a protein called caspase-
activated DNAse or CAD 79. Under conditions of failed apoptosis, low-levels of  
caspases activity might trigger limited CAD activity leading to DNA damage. 
Indeed, glioma cells and mouse fibroblasts surviving TRAIL treatment engage 
DNA damage in a caspase and CAD-dependent manner 72 (Figure 3).  
 
 Most stimuli, including established anti-cancer therapies such as 
etoposide, paclitaxel or more recently developed BH3 mimetics, initiate 
apoptosis through the intrinsic pathway by engaging or sensitising to MOMP 
80. Based on live-cell imaging studies, the binary all-or-nothing nature of 
MOMP makes it difficult to envision how intrinsic stimuli could act in any other 
way but to kill a cell. However, several years ago we demonstrated that some 
mitochondria could resist MOMP, due to higher anti-apoptotic Bcl-2 protein 
expression, a situation we termed incomplete MOMP or iMOMP 81. These 
findings revealed intracellular heterogeneity in the sensitivity of mitochondria 
to MOMP. Recently, we have found that different stresses applied at sub-
lethal doses can engage MOMP in limited numbers mitochondria without 
killing the cell - we call this minority MOMP 71. Importantly, minority MOMP 
triggers sub-lethal caspase activity (similar to TRAIL), causing DNA-damage 
and genome instability in a CAD-dependent manner (Figure 3). In such a 
manner, repeated engagement of sub-lethal stress was shown to promote 
transformation and tumourigenesis in a MOMP and caspase-dependent 
manner 71.  
 
 Other studies support oncogenic effects of failed apoptosis. For 
instance, mitotic arrest has been shown to trigger DNA damage in a MOMP 
and caspase-dependent manner 82, 83. Moreover, transgenic expression of 
pro-apoptotic BAX has been found to promote lymphomagenesis -
characterised by genomic instability- in a manner that is suppressed by co-
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expressing anti-apoptotic BCL-2 84. Besides CAD, the mitochondrial nuclease 
Endo G has also been found to promote radiation-induced DNA damage and 
transformation 73. Implicating a direct role for caspase-3, deletion of caspase-
3 inhibited transformation following DNA-damage and reduced 
tumourigenesis in a chemically induced model of skin-cancer 73.  
 
Is there any evidence that DNA damage induced by failed apoptosis 
actually promotes cancer? One possibility is the following. The mixed lineage 
leukaemia (MLL) gene encodes a histone methylating enzyme (KMT2A) that 
functions as an epigenetic regulator. The MLL locus is highly susceptible to 
breakage and rearrangement, this can generate oncogenic MLL fusion 
proteins which lack methyltransferase activity 85. Rearrangements in MLL are 
recurrent oncogenic drivers in a variety of leukaemias including acute myeloid 
leukaemia (AML) and acute lymphoid leukaemia (ALL) 86. Importantly from the 
perspective of this discussion, MLL is the most commonly re-arranged gene in 
therapy-related neoplasms including AML and MDS 86. While MLL 
rearrangements are associated with topoisomerase II inhibitor treatment, 
several lines of evidence argue that this is not solely through inhibition of 
topoisomerase II function; in these settings apoptosis may play a role in 
generating MLL rearrangements. Indeed, a variety of studies have shown that 
inhibition of caspase or CAD function reduces the incidence of MLL 
rearrangements following topoisomerase II inhibitor treatment 87-89. This 
suggests a model whereby failed apoptosis, by causing caspase and CAD-
dependent breakpoints in the MLL gene, promotes oncogenic re-
arrangements in surviving cells.  
 
 How else might failed apoptosis-induced DNA damage/genome-
instability impact on cancer? In inflammation-associated cancers, while DNA-
damage is required for tumourigenesis, often the cause of DNA-damage 
remains unclear 90. Potentially, engagement of failed apoptosis could serve to 
induce DNA-damage under inflammatory conditions. Another possibility may 
be by promoting acquired resistance to apoptosis-inducing anti-cancer 
therapies. Supporting this idea, repeated culturing of cells in the BCL-2 
targeting BH3 mimetic ABT-199, led to the development of acquired 
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resistance 91. Surprisingly, resistance was found to be due to a mutation in 
BCL-2 that allowed it to maintain anti-apoptotic function but prevented its 
inhibition by ABT-199 91. DNA damage engaged by failed apoptosis may 
potentially have given rise to the acquisition of resistance in this case, 
although it also remains formally possible that a pre-existing clone harboring 
these BCL-2 mutations may have been selected for by drug treatment. Finally, 
it is also important to note that DNA damage engaged during failed apoptosis 
may also have protective, anti-cancer functions. For example, BH3-mimetic 
treatment can engage senescence - where cells irreversibly enter cell cycle 
arrest - in a caspase-dependent manner 92. This and other studies, support a 
role for DNA damage induced by failed apoptosis in feeding forward to 
engage p53 transcriptional responses 82, 83, 92. By doing-so, p53 can exert 
tumour suppressor function. Importantly, non-lethal functions for caspases 
have also been described in various physiological processes including 
differentiation, memory and neurite pruning 93. However it is unknown whether 
caspase activity also engages DNA-damage during these processes and, if 
not, how cells would suppress these effects. 
 
Non-canonical oncogenic roles for "apoptotic" proteins  
 Besides their role in engaging apoptosis, a variety of non-apoptotic 
roles have been ascribed to almost all proteins classically viewed as apoptotic 
94-96. Some of these non-apoptotic functions may be oncogenic. For brevity, 
we have restricted our discussion of non-apoptotic protein functions and 
oncogenesis to death-receptor signalling. Bcl-2 family proteins have been 
implicated in a variety of non-apoptotic functions that may also impinge on 
tumourigenesis. These include regulation of calcium homeostasis, metastasis 
and autophagy - although how they regulate the latter remains controversial 
97-100.  
 
 Focusing upon the death-receptors TRAIL and FAS, our discussion 
highlights that any consideration of pro-oncogenic effects of apoptosis 
signaling must also take into account these non-canonical functions (Figure 
3). As discussed, many tumour types are selectively sensitive to TRAIL-
induced apoptosis due to selective expression (relative to many normal 
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tissues) of TRAIL-receptor 101. While provides therapeutic opportunities, it 
suggests that cancer cells must gain some advantage from expressing TRAIL 
receptor. Addressing this, a recent study has shown that TRAIL receptor 
(TRAIL-R) signaling can promote cancer independent of its role in canonical 
apoptosis signaling 102. Here the authors found in vivo that TRAIL-R signaling 
could promote a variety of effects including invasion, proliferation and 
migration independently of its apoptotic function but dependent upon PI3K 
signaling. In line with functional importance, prevention of TRAIL-R signaling 
(through deletion of TRAIL-R) reduces metastasis while increasing survival in 
a KRAS-driven mouse model of pancreatic adenocarcinoma 102. In clinical 
support, high TRAIL receptor 2 expression correlates with reduced 
metastasis-free survival in human KRAS-driven cancers 102. In other in vitro 
settings, TRAIL-R signaling has also been found to stimulate cell migration in 
a caspase-dependent manner 103. In a process dependent on failed apoptosis, 
TRAIL-R signaling can lead to caspase-dependent cleavage of ROCK1 
kinase, causing activation of Rho GTPase, membrane blebbing and cell 
migration 103, 104. In sum, these findings suggest that inhibition of TRAIL-R 
signaling may provide therapeutic benefit in some settings whereas TRAIL-R 
agonists could engage unwanted side effects in specific tumour types.  
 
Engagement of FAS receptor (also called CD95 or APO-1) triggers 
extrinsic apoptosis in a manner similar to TRAIL. Like TRAIL, a variety of non-
apoptotic, pro-oncogenic functions have also been described for FAS 
signaling, including stimulation of proliferation and migration 105. Increased 
levels of FAS ligand are observed in a variety of cancers, and inhibition of 
FAS signalling (via deletion of FAS) inhibits tumourigenesis in different mouse 
tumour models 106. Besides having pro-proliferative effects, FAS signaling can 
also exert pro-survival functions. This paradoxical role has been revealed in 
various cell types, including cancer stem cells, where elimination of FAS 
signalling actually causes cell death 107, 108. The mechanism(s) underlying this 
type of cell death, termed death induced by CD95R/L elimination (DICE), is 
unclear but does not appear to involve any known regulated pathway of cell 
death 108.   
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Modeling oncogenic effects of apoptosis 
 Mouse models have proven invaluable in helping define the role of 
apoptosis in tumour suppression, anti-cancer therapy and as a bone fide 
therapeutic target 19, 20, 109-111. Investigating the pro-oncogenic potential of 
apoptosis, we propose that mouse models should be extended to address 
the following interrelated questions: 1) can apoptosis exert a pro-
oncogenic function during tumourigenesis ? 2) do we observe correlations 
between sub-lethal caspase activation, tumourigenesis and treatment 
responses?    
 
I order to ask if apoptosis can exert tumour promoting functions, 
given that apoptosis has clear tumour suppressor functions, a key 
challenge will be to develop models that permit temporal inhibition or 
induction of apoptosis during cancer progression. Nevertheless, inducible 
systems based around tamoxifen/ER type control methods or degron-
based approaches should facilitate this approach 112, 113. In a 
complementary approach, experimentally engaging different levels of 
tumour cell apoptosis in vivo would directly allow one to test the effects of 
tumour cell apoptosis on tumour progression. To this end, we have 
developed a method called mito-priming, which should prove useful 114.  
In parallel, it will be necessary to develop ways to report processes 
such as failed apoptosis or sub-lethal caspases activation in vivo to 
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ascertain whether these correlate with tumour progression. Along these 
lines, fluorescent reporters have recently been developed that accurately 
detect caspase activity even at sub lethal levels 71, 115. While apoptosis has 
been extensively imaged in vitro very few studies have extended these 
analyses to an in vivo setting 116-118. Particularly with respect to a possible 
role for apoptotic/immune cell interactions in promoting cancer, we 
speculate that real-time intravital imaging of tumour cell death may 
provide compelling new insights into this process.  
 
Targeting apoptosis - pushing over the edge and pulling back 
from the brink  
 How can we better target apoptosis by improving tumour cell killing 
while preventing unwanted off-target effects? One possibility might be to 
induce intrinsic apoptosis while inhibiting caspase activity (Figure 4). Although 
this may seem counter-intuitive, as previously discussed, inhibition of caspase 
function does not ultimately protect against cell death following MOMP 12. 
Triggering apoptosis in the presence of caspase inhibitors may prevent 
against detrimental caspase-dependent effects. Supporting this idea, some 
studies have shown a positive effect of caspase-inhibition in combination with 
chemo- or radiotherapy 119, 120. These potentiating effects may be due to 
various mechasnisms including inhibition of tumour vascularization and 
enhanced anti-tumour immunity 119, 120. Nevertheless, inhibition of caspase 
function may have untoward and potentially unwanted effects. For example, 
MOMP in the absence of caspase activity can engage interferon responses 
dependent upon activation of the STING pathway 121, 122. The role of STING-
dependent interferon signaling in cancer is complex such that it can exert both 
pro- and anti-tumourigenic effects 123, 124. Moreover, caspase inhibitors can 
completely block extrinsic apoptosis and are thereby unsuitable when this is 
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expected to exert a therapeutic benefit. Another strategy might be to target 
specific, caspase-dependent effects, for example by blocking the activity of 
PGE2 generated by apoptotic cells, using inhibitors such as celecoxib 43.  
 
The overall balance between cell proliferation and death dictates 
whether a tumour grows or regresses. Besides tumour-intrinsic mechanisms 
(e.g. apoptotic sensitivity) affecting this, cell death triggered by anti-tumour 
immunity also plays an important role in regulating this balance 125. It is now 
widely accepted that immune cells can be both anti- and pro-tumourigenic 125. 
First, they can prevent cancer by eliminating pre-cancerous lesions (immune 
surveillance) and increased tumour infiltration by T and NK cells correlates 
with improved prognosis for a number of malignancies 126. Secondly, the 
same immune response can also promote cancer growth 126.  Regarding the 
later effect, tumour cell death can activate macrophages towards a tumour 
promoting state. Understanding how this occurs should reveal possible ways 
to block it. Additional approaches might be combining apoptosis-inducing anti-
cancer therapies with modulators of macrophage (TAM) signaling. For 
example, inhibition of CSF-1 signaling (the main trophic support factor for 
macrophages) has been shown to have multiple beneficial effects by either 
depleting TAM or switching them towards a more tumour suppressor mode 
127, 128. 
 
 In cancer cells that have engaged caspase activity but survived, how 
do we push them over the edge and kill them? One avenue may be by 
antagonising endogenous caspase inhibitors such as XIAP using inhibitors 
called SMAC mimetics 129 (Figure 4). However, there are also various other 
XIAP-independent mechanisms whereby caspase activity can be restrained 9, 
130. Another possibility could be to enhance caspase cleavage of specific 
substrates, thereby triggering death. A prime candidate might be BID, of 
which minimal cleavage is required to kill a cell 131. A potentially targetable 
possibility is using inhibitors for the kinase(s) that phosphorylate BID and 
inhibit its caspase-mediated activation 132, 133. Finally, cancer cells undergoing 
sub-lethal caspase activity may be more sensitive than healthy tissue to 
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additional caspase activity providing a therapeutic window for direct small-
molecule caspase activators 134.  
  
Outlook 
 Clearly, apoptosis has abundant beneficial effects in restraining and 
treating cancer - the progression of BH3 mimetics to late-stage clinical trial 
attests to this. Nevertheless, as we have discussed, apoptosis is responsible 
for a variety of effects that may be tumour promoting. As such, tumour 
progression may be governed not only by the balance between proliferation 
and cell death, but also by the balance between tumour suppressor and 
oncogenic functions of apoptotic signalling. Going forward, the relative 
importance of these oncogenic versus tumour suppressor effects should be 
defined in vivo. The importance of oncogenic apoptotic effects may also be 
tumour-stage or tumour-type specific; in this respect, studies investigating 
apoptotic levels and/or BCL-2 protein expression with prognostic outcome 
(Table 1) should help guide investigation to specific tumour types. Finally, the 
end-goal is to investigate clinical relevance of these effects in primary patient 
samples. Beyond defining this dark side of apoptosis, some of these effects 
also offer promising potential to improve cancer cell killing; for example, 
understanding how cancer cells tolerate failed apoptosis and survive could 
provide new strategies to subvert this process in order to kill them.  
 
Besides apoptosis, it is likely that other forms of cell death similarly 
impact on cancer in a multi-faceted manner. For example, inflammation 
associated with non-regulated, necrotic cell death can have both tumour 
promoting and inhibitory effects 135, 136. Taking all these considerations into 
account, we envision that an improved understanding of the role of apoptosis 
in cancer will allow us to fully harness its potential as a therapeutic target. 
  
Acknowledgements 
 G.I. is funded by an EMBO Advanced Fellowship (aALTF 772-2015) 
and Tenovus Scotland. The Tait lab is funded by Cancer Research UK 
 20
(C40872/A20145), the Royal Society, BBSRC (BB/K008374/1), the European 
Union, Breast Cancer Now (2015NovSPR589) and Tenovus Scotland. S.T. is 
a Royal Society University Research Fellow. Tait Lab url: 
http://www.beatson.gla.ac.uk/cancer-metabolism-growth-and-
survival/stephen-tait-mitochondria-and-cell-death.html 
 
 
 
  
 21
Reference 
1. Green, D.R. Means to an end : apoptosis and other cell death 
mechanisms (Cold Spring Harbor Laboratory Press, Cold Spring 
Harbor, N.Y., 2011). 
2. Mattson, M.P. Apoptosis in neurodegenerative disorders. Nat Rev Mol 
Cell Biol 1, 120-9 (2000). 
3. Nagata, S. Apoptosis and autoimmune diseases. Ann N Y Acad Sci 
1209, 10-6 (2010). 
4. Hanahan, D. & Weinberg, R.A. The hallmarks of cancer. Cell 100, 57-
70 (2000). 
5. Delbridge, A.R., Grabow, S., Strasser, A. & Vaux, D.L. Thirty years of 
BCL-2: translating cell death discoveries into novel cancer therapies. 
Nat Rev Cancer 16, 99-109 (2016). 
6. Letai, A.G. Diagnosing and exploiting cancer's addiction to blocks in 
apoptosis. Nat Rev Cancer 8, 121-32 (2008). 
7. Roberts, A.W. et al. Targeting BCL2 with Venetoclax in Relapsed 
Chronic Lymphocytic Leukemia. N Engl J Med 374, 311-22 (2016). 
8. Taylor, R.C., Cullen, S.P. & Martin, S.J. Apoptosis: controlled 
demolition at the cellular level. Nat Rev Mol Cell Biol 9, 231-41 (2008). 
9. Tait, S.W. & Green, D.R. Mitochondria and cell death: outer membrane 
permeabilization and beyond. Nat Rev Mol Cell Biol 11, 621-32 (2010). 
10. Li, H., Zhu, H., Xu, C.J. & Yuan, J. Cleavage of BID by caspase 8 
mediates the mitochondrial damage in the Fas pathway of apoptosis. 
Cell 94, 491-501 (1998). 
11. Luo, X., Budihardjo, I., Zou, H., Slaughter, C. & Wang, X. Bid, a Bcl2 
interacting protein, mediates cytochrome c release from mitochondria 
in response to activation of cell surface death receptors. Cell 94, 481-
90 (1998). 
12. Tait, S.W., Ichim, G. & Green, D.R. Die another way--non-apoptotic 
mechanisms of cell death. J Cell Sci 127, 2135-44 (2014). 
13. Gama, V. et al. The E3 ligase PARC mediates the degradation of 
cytosolic cytochrome c to promote survival in neurons and cancer cells. 
Sci Signal 7, ra67 (2014). 
14. Wright, K.M., Linhoff, M.W., Potts, P.R. & Deshmukh, M. Decreased 
apoptosome activity with neuronal differentiation sets the threshold for 
strict IAP regulation of apoptosis. J Cell Biol 167, 303-13 (2004). 
15. Colell, A. et al. GAPDH and autophagy preserve survival after 
apoptotic cytochrome c release in the absence of caspase activation. 
Cell 129, 983-97 (2007). 
16. Czabotar, P.E., Lessene, G., Strasser, A. & Adams, J.M. Control of 
apoptosis by the BCL-2 protein family: implications for physiology and 
therapy. Nat Rev Mol Cell Biol 15, 49-63 (2014). 
17. Llambi, F. et al. A unified model of mammalian BCL-2 protein family 
interactions at the mitochondria. Mol Cell 44, 517-31 (2011). 
18. Oltersdorf, T. et al. An inhibitor of Bcl-2 family proteins induces 
regression of solid tumours. Nature 435, 677-81 (2005). 
19. Strasser, A., Harris, A.W., Bath, M.L. & Cory, S. Novel primitive 
lymphoid tumours induced in transgenic mice by cooperation between 
myc and bcl-2. Nature 348, 331-3 (1990). 
 22
20. Fanidi, A., Harrington, E.A. & Evan, G.I. Cooperative interaction 
between c-myc and bcl-2 proto-oncogenes. Nature 359, 554-6 (1992). 
21. Vaux, D.L., Cory, S. & Adams, J.M. Bcl-2 gene promotes haemopoietic 
cell survival and cooperates with c-myc to immortalize pre-B cells. 
Nature 335, 440-2 (1988). 
22. Yonish-Rouach, E. et al. Wild-type p53 induces apoptosis of myeloid 
leukaemic cells that is inhibited by interleukin-6. Nature 352, 345-7 
(1991). 
23. Ni Chonghaile, T. et al. Pretreatment mitochondrial priming correlates 
with clinical response to cytotoxic chemotherapy. Science 334, 1129-
33 (2011). 
24. Montero, J. et al. Drug-induced death signaling strategy rapidly predicts 
cancer response to chemotherapy. Cell 160, 977-89 (2015). 
25. Adams, J.M. & Cory, S. The Bcl-2 apoptotic switch in cancer 
development and therapy. Oncogene 26, 1324-37 (2007). 
26. Certo, M. et al. Mitochondria primed by death signals determine cellular 
addiction to antiapoptotic BCL-2 family members. Cancer Cell 9, 351-
65 (2006). 
27. Lopez, J. & Tait, S.W. Mitochondrial apoptosis: killing cancer using the 
enemy within. Br J Cancer 112, 957-62 (2015). 
28. Wyllie, A.H. The biology of cell death in tumours. Anticancer Res 5, 
131-6 (1985). 
29. Naresh, K.N., Lakshminarayanan, K., Pai, S.A. & Borges, A.M. 
Apoptosis index is a predictor of metastatic phenotype in patients with 
early stage squamous carcinoma of the tongue: a hypothesis to 
support this paradoxical association. Cancer 91, 578-84 (2001). 
30. Jalalinadoushan, M., Peivareh, H. & Azizzadeh Delshad, A. Correlation 
between Apoptosis and Histological Grade of Transitional Cell 
Carcinoma of Urinary Bladder. Urol J 1, 177-9 (2004). 
31. Sun, B. et al. Extent, relationship and prognostic significance of 
apoptosis and cell proliferation in synovial sarcoma. Eur J Cancer Prev 
15, 258-65 (2006). 
32. Alcaide, J. et al. The role and prognostic value of apoptosis in 
colorectal carcinoma. BMC Clin Pathol 13, 24 (2013). 
33. de Jong, J.S., van Diest, P.J. & Baak, J.P. Number of apoptotic cells as 
a prognostic marker in invasive breast cancer. Br J Cancer 82, 368-73 
(2000). 
34. Del Gaizo Moore, V. et al. Chronic lymphocytic leukemia requires 
BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 
antagonist ABT-737. J Clin Invest 117, 112-21 (2007). 
35. Ryoo, H.D., Gorenc, T. & Steller, H. Apoptotic cells can induce 
compensatory cell proliferation through the JNK and the Wingless 
signaling pathways. Dev Cell 7, 491-501 (2004). 
36. Huh, J.R., Guo, M. & Hay, B.A. Compensatory proliferation induced by 
cell death in the Drosophila wing disc requires activity of the apical cell 
death caspase Dronc in a nonapoptotic role. Curr Biol 14, 1262-6 
(2004). 
37. Perez-Garijo, A., Martin, F.A. & Morata, G. Caspase inhibition during 
apoptosis causes abnormal signalling and developmental aberrations 
in Drosophila. Development 131, 5591-8 (2004). 
 23
38. Li, F. et al. Apoptotic cells activate the "phoenix rising" pathway to 
promote wound healing and tissue regeneration. Sci Signal 3, ra13 
(2010). 
39. Atsumi, G. et al. Fas-induced arachidonic acid release is mediated by 
Ca2+-independent phospholipase A2 but not cytosolic phospholipase 
A2, which undergoes proteolytic inactivation. J Biol Chem 273, 13870-7 
(1998). 
40. Revesz, L. Effect of tumour cells killed by x-rays upon the growth of 
admixed viable cells. Nature 178, 1391-2 (1956). 
41. Chaurio, R. et al. UVB-irradiated apoptotic cells induce accelerated 
growth of co-implanted viable tumor cells in immune competent mice. 
Autoimmunity 46, 317-22 (2013). 
42. Huang, Q. et al. Caspase 3-mediated stimulation of tumor cell 
repopulation during cancer radiotherapy. Nat Med 17, 860-6 (2011). 
43. Kurtova, A.V. et al. Blocking PGE2-induced tumour repopulation 
abrogates bladder cancer chemoresistance. Nature 517, 209-13 
(2015). 
44. Zelenay, S. et al. Cyclooxygenase-Dependent Tumor Growth through 
Evasion of Immunity. Cell 162, 1257-70 (2015). 
45. Kruiswijk, F., Labuschagne, C.F. & Vousden, K.H. p53 in survival, 
death and metabolic health: a lifeguard with a licence to kill. Nat Rev 
Mol Cell Biol 16, 393-405 (2015). 
46. Bondar, T. & Medzhitov, R. p53-mediated hematopoietic stem and 
progenitor cell competition. Cell Stem Cell 6, 309-22 (2010). 
47. Marusyk, A., Porter, C.C., Zaberezhnyy, V. & DeGregori, J. Irradiation 
selects for p53-deficient hematopoietic progenitors. PLoS Biol 8, 
e1000324 (2010). 
48. Villunger, A. et al. p53- and drug-induced apoptotic responses 
mediated by BH3-only proteins puma and noxa. Science 302, 1036-8 
(2003). 
49. Jeffers, J.R. et al. Puma is an essential mediator of p53-dependent and 
-independent apoptotic pathways. Cancer Cell 4, 321-8 (2003). 
50. Garrison, S.P. et al. Selection against PUMA gene expression in Myc-
driven B-cell lymphomagenesis. Mol Cell Biol 28, 5391-402 (2008). 
51. Michalak, E.M. et al. Puma and to a lesser extent Noxa are 
suppressors of Myc-induced lymphomagenesis. Cell Death Differ 16, 
684-96 (2009). 
52. Michalak, E.M. et al. Apoptosis-promoted tumorigenesis: gamma-
irradiation-induced thymic lymphomagenesis requires Puma-driven 
leukocyte death. Genes Dev 24, 1608-13 (2010). 
53. Labi, V. et al. Apoptosis of leukocytes triggered by acute DNA damage 
promotes lymphoma formation. Genes Dev 24, 1602-7 (2010). 
54. Qiu, W. et al. PUMA-mediated apoptosis drives chemical 
hepatocarcinogenesis in mice. Hepatology 54, 1249-58 (2011). 
55. Pierce, R.H., Vail, M.E., Ralph, L., Campbell, J.S. & Fausto, N. Bcl-2 
expression inhibits liver carcinogenesis and delays the development of 
proliferating foci. Am J Pathol 160, 1555-60 (2002). 
56. Orlik, J. et al. The BH3-only protein BID impairs the p38-mediated 
stress response and promotes hepatocarcinogenesis during chronic 
liver injury in mice. Hepatology 62, 816-28 (2015). 
 24
57. Bai, L., Ni, H.M., Chen, X., DiFrancesca, D. & Yin, X.M. Deletion of Bid 
impedes cell proliferation and hepatic carcinogenesis. Am J Pathol 
166, 1523-32 (2005). 
58. Bejar, R. & Steensma, D.P. Recent developments in myelodysplastic 
syndromes. Blood 124, 2793-803 (2014). 
59. Guirguis, A.A. et al. PUMA promotes apoptosis of hematopoietic 
progenitors driving leukemic progression in a mouse model of 
myelodysplasia. Cell Death Differ (2016). 
60. Slape, C.I. et al. Inhibition of apoptosis by BCL2 prevents leukemic 
transformation of a murine myelodysplastic syndrome. Blood 120, 
2475-83 (2012). 
61. Arandjelovic, S. & Ravichandran, K.S. Phagocytosis of apoptotic cells 
in homeostasis. Nat Immunol 16, 907-17 (2015). 
62. Tang, J. et al. Upregulation of fractalkine contributes to the proliferative 
response of prostate cancer cells to hypoxia via promoting the G1/S 
phase transition. Mol Med Rep (2015). 
63. Tardaguila, M. & Manes, S. CX3CL1 at the crossroad of EGF signals: 
Relevance for the progression of ERBB2 breast carcinoma. 
Oncoimmunology 2, e25669 (2013). 
64. Elliott, M.R. et al. Nucleotides released by apoptotic cells act as a find-
me signal to promote phagocytic clearance. Nature 461, 282-6 (2009). 
65. Spychala, J. Tumor-promoting functions of adenosine. Pharmacol Ther 
87, 161-73 (2000). 
66. Gregory, C.D. & Pound, J.D. Cell death in the neighbourhood: direct 
microenvironmental effects of apoptosis in normal and neoplastic 
tissues. J Pathol 223, 177-94 (2011). 
67. Noy, R. & Pollard, J.W. Tumor-associated macrophages: from 
mechanisms to therapy. Immunity 41, 49-61 (2014). 
68. Ford, C.A. et al. Oncogenic properties of apoptotic tumor cells in 
aggressive B cell lymphoma. Curr Biol 25, 577-88 (2015). 
69. Stanford, J.C. et al. Efferocytosis produces a prometastatic landscape 
during postpartum mammary gland involution. J Clin Invest 124, 4737-
52 (2014). 
70. Schedin, P.J. & Watson, C.J. The complexity of the relationships 
between age at first birth and breast cancer incidence curves implicate 
pregnancy in cancer initiation as well as promotion of existing lesions. 
Preface. J Mammary Gland Biol Neoplasia 14, 85-6 (2009). 
71. Ichim, G. et al. Limited mitochondrial permeabilization causes DNA 
damage and genomic instability in the absence of cell death. Mol Cell 
57, 860-72 (2015). 
72. Lovric, M.M. & Hawkins, C.J. TRAIL treatment provokes mutations in 
surviving cells. Oncogene 29, 5048-60 (2010). 
73. Liu, X. et al. Caspase-3 promotes genetic instability and 
carcinogenesis. Mol Cell 58, 284-96 (2015). 
74. Goldstein, J.C., Waterhouse, N.J., Juin, P., Evan, G.I. & Green, D.R. 
The coordinate release of cytochrome c during apoptosis is rapid, 
complete and kinetically invariant. Nat Cell Biol 2, 156-62 (2000). 
75. Rehm, M., Dussmann, H. & Prehn, J.H. Real-time single cell analysis 
of Smac/DIABLO release during apoptosis. J Cell Biol 162, 1031-43 
(2003). 
 25
76. Rehm, M., Huber, H.J., Dussmann, H. & Prehn, J.H. Systems analysis 
of effector caspase activation and its control by X-linked inhibitor of 
apoptosis protein. EMBO J 25, 4338-49 (2006). 
77. Walczak, H. et al. Tumoricidal activity of tumor necrosis factor-related 
apoptosis-inducing ligand in vivo. Nat Med 5, 157-63 (1999). 
78. Albeck, J.G. et al. Quantitative analysis of pathways controlling 
extrinsic apoptosis in single cells. Mol Cell 30, 11-25 (2008). 
79. Enari, M. et al. A caspase-activated DNase that degrades DNA during 
apoptosis, and its inhibitor ICAD. Nature 391, 43-50 (1998). 
80. Galluzzi, L., Larochette, N., Zamzami, N. & Kroemer, G. Mitochondria 
as therapeutic targets for cancer chemotherapy. Oncogene 25, 4812-
30 (2006). 
81. Tait, S.W. et al. Resistance to caspase-independent cell death requires 
persistence of intact mitochondria. Dev Cell 18, 802-13 (2010). 
82. Orth, J.D., Loewer, A., Lahav, G. & Mitchison, T.J. Prolonged mitotic 
arrest triggers partial activation of apoptosis, resulting in DNA damage 
and p53 induction. Mol Biol Cell 23, 567-76 (2012). 
83. Colin, D.J., Hain, K.O., Allan, L.A. & Clarke, P.R. Cellular responses to 
a prolonged delay in mitosis are determined by a DNA damage 
response controlled by Bcl-2 family proteins. Open Biol 5, 140156 
(2015). 
84. Luke, J.J., Van De Wetering, C.I. & Knudson, C.M. Lymphoma 
development in Bax transgenic mice is inhibited by Bcl-2 and 
associated with chromosomal instability. Cell Death Differ 10, 740-8 
(2003). 
85. Rao, R.C. & Dou, Y. Hijacked in cancer: the KMT2 (MLL) family of 
methyltransferases. Nat Rev Cancer 15, 334-46 (2015). 
86. Gole, B. & Wiesmuller, L. Leukemogenic rearrangements at the mixed 
lineage leukemia gene (MLL)-multiple rather than a single mechanism. 
Front Cell Dev Biol 3, 41 (2015). 
87. Hars, E.S., Lyu, Y.L., Lin, C.P. & Liu, L.F. Role of apoptotic nuclease 
caspase-activated DNase in etoposide-induced treatment-related acute 
myelogenous leukemia. Cancer Res 66, 8975-9 (2006). 
88. Sim, S.P. & Liu, L.F. Nucleolytic cleavage of the mixed lineage 
leukemia breakpoint cluster region during apoptosis. J Biol Chem 276, 
31590-5 (2001). 
89. Betti, C.J., Villalobos, M.J., Diaz, M.O. & Vaughan, A.T. Apoptotic 
stimuli initiate MLL-AF9 translocations that are transcribed in cells 
capable of division. Cancer Res 63, 1377-81 (2003). 
90. Trinchieri, G. Cancer and inflammation: an old intuition with rapidly 
evolving new concepts. Annu Rev Immunol 30, 677-706 (2012). 
91. Fresquet, V., Rieger, M., Carolis, C., Garcia-Barchino, M.J. & Martinez-
Climent, J.A. Acquired mutations in BCL2 family proteins conferring 
resistance to the BH3 mimetic ABT-199 in lymphoma. Blood 123, 
4111-9 (2014). 
92. Song, J.H., Kandasamy, K., Zemskova, M., Lin, Y.W. & Kraft, A.S. The 
BH3 mimetic ABT-737 induces cancer cell senescence. Cancer Res 
71, 506-15 (2011). 
93. Fuchs, Y. & Steller, H. Programmed cell death in animal development 
and disease. Cell 147, 742-58 (2011). 
 26
94. Hardwick, J.M. & Soane, L. Multiple functions of BCL-2 family proteins. 
Cold Spring Harb Perspect Biol 5 (2013). 
95. Hyman, B.T. & Yuan, J. Apoptotic and non-apoptotic roles of caspases 
in neuronal physiology and pathophysiology. Nat Rev Neurosci 13, 
395-406 (2012). 
96. Kilbride, S.M. & Prehn, J.H. Central roles of apoptotic proteins in 
mitochondrial function. Oncogene 32, 2703-11 (2013). 
97. Bonneau, B., Prudent, J., Popgeorgiev, N. & Gillet, G. Non-apoptotic 
roles of Bcl-2 family: the calcium connection. Biochim Biophys Acta 
1833, 1755-65 (2013). 
98. Pedro, J.M. et al. BAX and BAK1 are dispensable for ABT-737-induced 
dissociation of the BCL2-BECN1 complex and autophagy. Autophagy 
11, 452-9 (2015). 
99. Lindqvist, L.M., Heinlein, M., Huang, D.C. & Vaux, D.L. Prosurvival Bcl-
2 family members affect autophagy only indirectly, by inhibiting Bax 
and Bak. Proc Natl Acad Sci U S A 111, 8512-7 (2014). 
100. Choi, S. et al. Bcl-xL promotes metastasis independent of its anti-
apoptotic activity. Nat Commun 7, 10384 (2016). 
101. Dimberg, L.Y. et al. On the TRAIL to successful cancer therapy? 
Predicting and counteracting resistance against TRAIL-based 
therapeutics. Oncogene 32, 1341-50 (2013). 
102. von Karstedt, S. et al. Cancer cell-autonomous TRAIL-R signaling 
promotes KRAS-driven cancer progression, invasion, and metastasis. 
Cancer Cell 27, 561-73 (2015). 
103. Somasekharan, S.P. et al. TRAIL promotes membrane blebbing, 
detachment and migration of cells displaying a dysfunctional intrinsic 
pathway of apoptosis. Apoptosis 18, 324-36 (2013). 
104. Ehrenschwender, M. et al. Mutant PIK3CA licenses TRAIL and CD95L 
to induce non-apoptotic caspase-8-mediated ROCK activation. Cell 
Death Differ 17, 1435-47 (2010). 
105. Peter, M.E. et al. The role of CD95 and CD95 ligand in cancer. Cell 
Death Differ 22, 885-6 (2015). 
106. Chen, L. et al. CD95 promotes tumour growth. Nature 465, 492-6 
(2010). 
107. Hadji, A. et al. Death induced by CD95 or CD95 ligand elimination. Cell 
Rep 7, 208-22 (2014). 
108. Ceppi, P. et al. CD95 and CD95L promote and protect cancer stem 
cells. Nat Commun 5, 5238 (2014). 
109. Schmitt, C.A., Rosenthal, C.T. & Lowe, S.W. Genetic analysis of 
chemoresistance in primary murine lymphomas. Nat Med 6, 1029-35 
(2000). 
110. Letai, A., Sorcinelli, M.D., Beard, C. & Korsmeyer, S.J. Antiapoptotic 
BCL-2 is required for maintenance of a model leukemia. Cancer Cell 6, 
241-9 (2004). 
111. Kelly, G.L. et al. Targeting of MCL-1 kills MYC-driven mouse and 
human lymphomas even when they bear mutations in p53. Genes Dev 
28, 58-70 (2014). 
112. Garcia, E.L. & Mills, A.A. Getting around lethality with inducible Cre-
mediated excision. Semin Cell Dev Biol 13, 151-8 (2002). 
 27
113. Todt, F. et al. Differential retrotranslocation of mitochondrial Bax and 
Bak. EMBO J 34, 67-80 (2015). 
114. Lopez, J. et al. Mito-priming as a method to engineer Bcl-2 addiction. 
Nat Commun 7, 10538 (2016). 
115. Zhang, J. et al. Visualization of caspase-3-like activity in cells using a 
genetically encoded fluorescent biosensor activated by protein 
cleavage. Nat Commun 4, 2157 (2013). 
116. Earley, S. et al. In vivo imaging of drug-induced mitochondrial outer 
membrane permeabilization at single-cell resolution. Cancer Res 72, 
2949-56 (2012). 
117. Ellenbroek, S.I. & van Rheenen, J. Imaging hallmarks of cancer in 
living mice. Nat Rev Cancer 14, 406-18 (2014). 
118. Janssen, A., Beerling, E., Medema, R. & van Rheenen, J. Intravital 
FRET imaging of tumor cell viability and mitosis during chemotherapy. 
PLoS One 8, e64029 (2013). 
119. Kim, K.W., Moretti, L. & Lu, B. M867, a novel selective inhibitor of 
caspase-3 enhances cell death and extends tumor growth delay in 
irradiated lung cancer models. PLoS One 3, e2275 (2008). 
120. Werthmoller, N., Frey, B., Wunderlich, R., Fietkau, R. & Gaipl, U.S. 
Modulation of radiochemoimmunotherapy-induced B16 melanoma cell 
death by the pan-caspase inhibitor zVAD-fmk induces anti-tumor 
immunity in a HMGB1-, nucleotide- and T-cell-dependent manner. Cell 
Death Dis 6, e1761 (2015). 
121. Rongvaux, A. et al. Apoptotic caspases prevent the induction of type I 
interferons by mitochondrial DNA. Cell 159, 1563-77 (2014). 
122. White, M.J. et al. Apoptotic caspases suppress mtDNA-induced 
STING-mediated type I IFN production. Cell 159, 1549-62 (2014). 
123. Ahn, J. et al. Inflammation-driven carcinogenesis is mediated through 
STING. Nat Commun 5, 5166 (2014). 
124. Ahn, J., Konno, H. & Barber, G.N. Diverse roles of STING-dependent 
signaling on the development of cancer. Oncogene 34, 5302-8 (2015). 
125. Schreiber, R.D., Old, L.J. & Smyth, M.J. Cancer immunoediting: 
integrating immunity's roles in cancer suppression and promotion. 
Science 331, 1565-70 (2011). 
126. Swann, J.B. & Smyth, M.J. Immune surveillance of tumors. J Clin 
Invest 117, 1137-46 (2007). 
127. Pyonteck, S.M. et al. CSF-1R inhibition alters macrophage polarization 
and blocks glioma progression. Nat Med 19, 1264-72 (2013). 
128. Ries, C.H. et al. Targeting tumor-associated macrophages with anti-
CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell 
25, 846-59 (2014). 
129. Fulda, S. & Vucic, D. Targeting IAP proteins for therapeutic intervention 
in cancer. Nat Rev Drug Discov 11, 109-24 (2012). 
130. Tait, S.W. & Green, D.R. Mitochondrial regulation of cell death. Cold 
Spring Harb Perspect Biol 5 (2013). 
131. Hellwig, C.T. et al. Real time analysis of tumor necrosis factor-related 
apoptosis-inducing ligand/cycloheximide-induced caspase activities 
during apoptosis initiation. J Biol Chem 283, 21676-85 (2008). 
132. Hellwig, C.T. et al. Activity of protein kinase CK2 uncouples Bid 
cleavage from caspase-8 activation. J Cell Sci 123, 1401-6 (2010). 
 28
133. Desagher, S. et al. Phosphorylation of bid by casein kinases I and II 
regulates its cleavage by caspase 8. Mol Cell 8, 601-11 (2001). 
134. Wolan, D.W., Zorn, J.A., Gray, D.C. & Wells, J.A. Small-molecule 
activators of a proenzyme. Science 326, 853-8 (2009). 
135. Vakkila, J. & Lotze, M.T. Inflammation and necrosis promote tumour 
growth. Nat Rev Immunol 4, 641-8 (2004). 
136. Grivennikov, S.I., Greten, F.R. & Karin, M. Immunity, inflammation, and 
cancer. Cell 140, 883-99 (2010). 
137. Berardo, M.D. et al. bcl-2 and apoptosis in lymph node positive breast 
carcinoma. Cancer 82, 1296-302 (1998). 
138. Vargas-Roig, L.M. et al. Prognostic value of Bcl-2 in breast cancer 
patients treated with neoadjuvant anthracycline based chemotherapy. 
Mol Oncol 2, 102-11 (2008). 
139. Karbowski, M., Norris, K.L., Cleland, M.M., Jeong, S.Y. & Youle, R.J. 
Role of Bax and Bak in mitochondrial morphogenesis. Nature 443, 658-
62 (2006). 
140. Dawson, S.J. et al. BCL2 in breast cancer: a favourable prognostic 
marker across molecular subtypes and independent of adjuvant 
therapy received. Br J Cancer 103, 668-75 (2010). 
141. Meterissian, S.H. et al. Bcl-2 is a useful prognostic marker in Dukes' B 
colon cancer. Ann Surg Oncol 8, 533-7 (2001). 
142. Watson, N.F. et al. Evidence that the p53 negative / Bcl-2 positive 
phenotype is an independent indicator of good prognosis in colorectal 
cancer: a tissue microarray study of 460 patients. World J Surg Oncol 
3, 47 (2005). 
143. Tomita, M. et al. Prognostic significance of bcl-2 expression in resected 
pN2 non-small cell lung cancer. Eur J Surg Oncol 29, 654-7 (2003). 
144. Anagnostou, V.K. et al. High expression of BCL-2 predicts favorable 
outcome in non-small cell lung cancer patients with non squamous 
histology. BMC Cancer 10, 186 (2010). 
145. Renouf, D.J. et al. BCL-2 expression is prognostic for improved 
survival in non-small cell lung cancer. J Thorac Oncol 4, 486-91 (2009). 
146. Pillai, K., Pourgholami, M.H., Chua, T.C. & Morris, D.L. Does the 
expression of BCL2 have prognostic significance in malignant 
peritoneal mesothelioma? Am J Cancer Res 3, 312-22 (2013). 
147. Kohler, T. et al. High Bad and Bax mRNA expression correlate with 
negative outcome in acute myeloid leukemia (AML). Leukemia 16, 22-9 
(2002). 
148. Kaparou, M. et al. Enhanced levels of the apoptotic BAX/BCL-2 ratio in 
children with acute lymphoblastic leukemia and high-risk features. 
Genet Mol Biol 36, 7-11 (2013). 
149. Hogarth, L.A. & Hall, A.G. Increased BAX expression is associated with 
an increased risk of relapse in childhood acute lymphocytic leukemia. 
Blood 93, 2671-8 (1999). 
150. Bairey, O., Zimra, Y., Shaklai, M., Okon, E. & Rabizadeh, E. Bcl-2, Bcl-
X, Bax, and Bak expression in short- and long-lived patients with 
diffuse large B-cell lymphomas. Clin Cancer Res 5, 2860-6 (1999). 
 
 
 29
Figure Legends 
Figure 1. Extrinsic and intrinsic apoptotic signalling pathways 
In the extrinsic apoptotic pathway, upon binding their cognate ligand, death 
receptors such as TRAIL and FAS activate initiator caspases-8 and -10 
through dimerisation mediated by adaptor proteins like FADD. Active 
caspase-8/-10 then cleave and activate the effector caspases 3 and 7, leading 
to apoptosis. The intrinsic (or mitochondrial) pathway of apoptosis requires 
mitochondrial outer-membrane permeabilisation (MOMP). Bcl-2 family 
proteins regulate mitochondrial permeabilisation. Cell stresses engage BH3-
only protein activation leading to BAX and BAK activity that triggers MOMP. 
Anti-apoptotic BCL-2 proteins counteract this. Following MOMP, mitochondrial 
intermembrane space proteins such as SMAC and cytochrome c are released 
into the cytosol. Cytochrome c interacts with APAF-1 triggering apoptosome 
assembly that activates caspase-9. Active caspase-9, in turn, activates 
caspase-3 and -7 leading to apoptosis. Mitochondrial release of SMAC 
facilitates apoptosis by blocking the caspase inhibitor XIAP. Caspase-8 
cleavage of BH3-only protein BID allows crosstalk between the extrinsic and 
intrinsic apoptotic pathways.  
 
Figure 2. Cell extrinsic pro-oncogenic effects of apoptotic cell death  
A. During apoptosis, caspases cleave and activate iPLA2 leading to the 
generation of PGE2. PGE2 can have pleiotropic effects on surrounding cells 
including pro-proliferative and immuno-silencing effects. B. Apoptosis of 
healthy cells can provide a vacant niche into which aberrant cells can 
proliferate ultimately leading to cancer. C. Apoptotic cells release a variety of 
“eat me” and “find me” molecules (FKN, ATP, LTF) to signal their removal by 
phagocytes. These signals can have a variety of pro-tumourigenic effects 
including turning tumour-associated macrophages (TAM) towards a pro-
oncogenic state. More precisely, TAM can stimulate angiogenesis, tumour cell 
motility and dissemination, prepare the pre-metastatic niche and silence 
immune surveillance by preventing NK and T cells to attack cancer cells.   
 
Figure 3. Oncogenic effects of engaging sub-lethal apoptotic signalling 
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Death receptors such as FAS and TRAIL can have non-apoptotic signalling 
functions that include promotion of growth, invasion and survival - all of which 
support cancer. Death receptors can also engage caspase dependent CAD 
activation leading to DNA-damage and mutagenesis.  Intrinsic apoptotic 
stimuli can engage limited mitochondrial permeabilisation (minority MOMP) 
that activates effector caspases to sub-lethal levels. The endonucleases CAD 
(or Caspase-activated DNase) and EndoG (released following MOMP) cleave 
the dsDNA in the internucleosomal linker causing oncogenic mutations.   
 
Figure 4. Enhancing apoptosis while minimising damage    
Possible enhancers of apoptosis are in boxed in red, inhibitors of unwanted 
effects are boxed in green.  Given they do not prevent death following 
widespread apoptotic MOMP, caspase inhibitors could prevent unwanted 
effects of caspase activity such as DNA-damage and PGE2 production. 
Inhibitors of PGE2 activity such as celecoxib could be applied in combination 
with apoptosis-inducing cancer therapies. Similarly, inhibiting CSF-1 signaling 
may either deplete TAM or switch them to an anti-tumourigenic phenotype. 
Following failed-apoptosis enhancement of caspase activity using SMAC-
mimetics (to antagonise XIAP) or other means may promote apoptosis. 
Likewise, direct, caspase-activating molecules may preferentially promote 
death in tumour cells that have undergone failed apoptosis that already have 
a low-level of caspase activity. Examples of therapeutic agents and their 
clinical trail status (source: clinicaltrials.gov) are also depicted in the figure. 
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Table 1. Correlation of high anti-apoptotic BCL-2 levels with good 
prognosis and high pro-apoptotic BAX levels with bad prognosis in 
various human cancers  
Correlation of increased anti-apoptotic BCL-2 expression and good cancer prognosis 
Cancer type  Comments Reference 
Breast cancer Increased BCL-2 expression (IHC) is significantly associated with better DFS and OS Berardo et al. 1998 
137 
  Following chemotherapy, higher BCL-2 expression (IHC) correlates with better survival rate 
Vargas-Roig et al. 
2008 138 
  Increased BCL-2 expression (IHC) correlates with improved overall survival  Neri et al. 2006 139 
  High BCL-2 (IHC) predicts better survival for early-stage cancers Dawson et al. 2010 140 
Colorectal cancer 
BCL-2 expression (IHC) correlates with improved survival in Duke's B colon 
carcinoma 
Meterissian et al. 2001 
141 
  
Increased BCL-2 expression (IHC) in the context of p53-deficiency correlates 
with improved survival Watson et al. 2005 
142 
NSCLC 
High BCL-2 expression (IHC) correlates with better survival in lung cancer 
patients with lymph node infiltration Tomita et al. 2003 
143 
  High BCL-2 (IHC) expressers have higher median survival Anagnostou et al. 2010 144 
  BCL-2 expression (IHC) is associated with increased survival Renouf et al. 2009 145 
Mesothelioma Patients with high BCL-2 expression (IHC) confers a survival advantage Pillai et al. 2013 146 
Correlation of increased pro-apoptoic BAX expression and poor cancer prognosis 
Cancer type  Comments Reference 
AML BAX and BAD high mRNA levels correlate with decreased survival 
Köhler et al. 2002 147  
ALL 
Increased BAX/BCL2 ratio (mRNA) in patients with high-risk of relapse such as 
chromosomal abnormalities Kaparou et al. 2013 148 
High BAX protein expression correlates with increased risk of relapse  Hogarth et al. 1999 149 
Non-Hodgkin's 
lymphoma BAX expression is associated with short survival 
Bairey et al. 1999 150 
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